There are several diagnostic procedures that can identify patients with recurrent or primary transitional cell carcinoma (TCC) of the bladder. Cystoscopy is the best tool and the golden standard against which the other tools have to be compared. In our experience the BTA test has proved more accurate than urinary cytology, above all in diagnosing low-grade, low-stage TCC of the bladder.
SarosdyM.F., DeVere WhiteR.W., SolowayM.S., SheinfeldJ., HudsonM.A., SchellhammerP.F., JarowenkoM.V., AdamsG., BlumensteinB.A.: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol., 154: 379–384, 1995.
2.
Bta International Key Evaluator Programme: The Bard BTA test: its role in bladder cancer management. Report from the BTA Key Evaluator Programme Forum, Amsterdam, June 13, 1995.
3.
D'HallewinM.A., BaertL.: Initial evaluation of the bladder tumour antigen test in superficial bladder cancer. J. Urol., 155: 475–476, 1996.
